Hpv particles and uses thereof
US-2019142925-A1 · May 16, 2019 · US
HPV particles and uses thereof
US10688172B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10688172-B2 |
| Application number | US-201816204019-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 29, 2018 |
| Priority date | Apr 13, 2009 |
| Publication date | Jun 23, 2020 |
| Grant date | Jun 23, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to modified HPV particles that can be used therapeutically. Modified HPV particles may be used to deliver therapeutic agents, including siRNA molecules. Modified HPV particles may be used for the treatment of diseases or conditions of mucosal tissue, including HPV (human papilloma virus) infection and HPV-related tumors.
First claim
Opening claim text (preview).
What is claimed is: 1. A method comprising: expressing in a host cell nucleic acids encoding modified papillomavirus L1 proteins that comprise an FG loop corresponding to the amino acid sequence of SEQ ID NO: 66; and isolating nanoparticles self-assembled from the papillomavirus L1 proteins. 2. The method of claim 1 , wherein the cell is selected from bacterial cells, insect cells, yeast cells, and mammalian cells. 3. The method of claim 2 , wherein the cell is a mammalian cell. 4. The method of claim 3 , wherein the mammalian cell is a 293T cell. 5. The method of claim 3 , wherein the mammalian cell is a 293FT cell. 6. The method of claim 1 , wherein the modified papillomavirus L1 proteins are modified human papillomavirus L1 proteins. 7. The method of claim 6 , wherein the modified papillomavirus L1 proteins are chimeric HPV16/31 L1 proteins. 8. The method of claim 1 , wherein the nanoparticles comprise the papillomavirus L1 proteins and papillomavirus L2 proteins. 9. A nanoparticle comprising a papillomavirus L1 protein comprising an FG loop comprising the amino acid sequence of SEQ ID NO: 66. 10. The nanoparticle of claim 9 , wherein the nanoparticle comprises at least one heterologous compound. 11. The nanoparticle of claim 10 , wherein the at least one heterologous compound comprises at least one therapeutic agent. 12. The nanoparticle of claim 10 , wherein the at least one heterologous compound comprises at least one diagnostic agent. 13. The nanoparticle of claim 9 , wherein the nanoparticle is a self-assembled nanoparticle. 14. The nanoparticle of claim 9 further comprising papillomavirus L2 capsid protein. 15. A method of delivering to a subject the nanoparticle of claim 9 . 16. The method of claim 15 , wherein the nanoparticle comprises at least one heterologous compound. 17. The method of claim 16 , wherein the at least one heterologous compound comprises at least one therapeutic agent. 18. The method of claim 16 , wherein the at least one heterologous compound comprises at least one diagnostic agent. 19. The method of claim 15 , wherein the nanoparticle is a self-assembled nanoparticle. 20. A papillomavirus L1 protein comprising an FG loop comprising the amino acid sequence of SEQ ID NO: 66.
Assignees
Inventors
Classifications
Cancer antigens · CPC title
Reproductive system [uterus, ovaries, cervix, testes] · CPC title
Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors · CPC title
- A61K39/12Primary
Viral antigens · CPC title
Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10688172B2 cover?
- The invention relates to modified HPV particles that can be used therapeutically. Modified HPV particles may be used to deliver therapeutic agents, including siRNA molecules. Modified HPV particles may be used for the treatment of diseases or conditions of mucosal tissue, including HPV (human papilloma virus) infection and HPV-related tumors.
- Who is the assignee on this patent?
- Inst Nat Sante Rech Med, Aura Biosciences Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K39/12. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).